In contrast, Wang et al. [91] revealed that PD-L1+ macrophages are immunostimulatory and associate with a good clinical outcome in patients with breast cancer, while PD-L1− macrophages are immunosuppressive and associate with poor clinical results. Here, CD274 is linked to breast cancer.